Abstract
Verapamil was introduced into a hospital-based urban/rural advanced life support (ALS) system for intravenous (IV) use in patients with symptomatic supraventricular tachyarrhythmias. During this trial period, IV verapamil was given to 24 patients, 12 (50%) of which benefited from its use. IV verapamil produced no harmful effects, and there was only one reported adverse effect (nausea) related to its administration. IV verapamil may be useful in the prehospital care of patients with symptomatic supraventricular tachyarrhythmias.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
